INOVIO Pharmaceuticals reported a first-quarter 2026 net loss of $19.7 million, or $0.28 per share, roughly in line with the prior year. Operating expenses fell to $21.9 million from $25.1 million as both R&D and G&A spending decreased.
The company ended March 31, 2026 with $37.7 million in cash, cash equivalents and short-term investments, before adding $16.0 million of net equity offering proceeds in April. Management expects this liquidity to fund operations into the first quarter of 2027, beyond the FDA’s target October 30, 2026 PDUFA date for lead candidate INO-3107.
The Biologics License Application for INO-3107 in recurrent respiratory papillomatosis is under active FDA review in the accelerated approval program, following completion of the mid-cycle review. INOVIO is preparing for a potential 2026 U.S. commercial launch and pursuing partnerships on other pipeline assets, including a GBM collaboration with Akeso for INO-5412.
https://www.stocktitan.net/sec-filings/INO/8-k-inovio-pharmaceuticals-inc-reports-material-event-8a85d209fa46.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.